HOOKIPA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8061 USD | -5.16% |
|
+5.39% | -0.48% |
Presenter SpeechVikram Purohit (Analysts)Great. Welcome, everyone. Let's go ahead and get star...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Companyâs replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.85
USD
Average target price
4.89
USD
Spread / Average Target
+475.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.48% | 84.11M | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Transcript : HOOKIPA Pharma Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 12
